CD4 and neoplasm: However, taken together, recent single-cell genomic and functional studies in patients have supported a direct role for CD4+ T cells in killing of diverse patient tumor types that is dependent on MHC class II recognition and granzymes and has provided some important initial insights into activating co-receptors (SLAMF7) or inhibitory inputs (e.g., by autologous Tregs) that regulate their activity.